Cisplatin (CDDP) is a potent antitumor drug used in the treatment of a variety of solid tumors. The purpose of the present study was to establish screening biomarker of exposure to CDDP using SOS chromotest. The ultimate goal of this screen is to facilitate the choice of an effective drug and the prognosis of the therapy. In the current screening protocol, the SOS chromotests were performed on the urine of Sprague-Dawley rats administered intravenously with CDDP. Urine samples were collected individually in the metabolic cage at 6 (U0–6) and 12 hours (U6–12) after treatment and were tested their DNA damaging effects. The urine samples obtained from the rats administered with 1 mg/kg CDDP did not induce SOS response in our experimental conditions. At a dose of 5 mg/kg, two out of five rat showed more than 50% increase in the DNA damaging effect compared to that of the control. The genotoxic effect was observed only in the U0–6, whereas the U6–12 were not genotoxic but cytotoxic to the test strain. Similar results were obtained at a dose of 10 mg/kg: 5 out of 10 rats showed SOS response and the U6–12 were also proven to be cytotoxic. These results suggest that the method presented in this study could be used as a biomarker of exposure to CDDP.
Basler, A., W. von der Hude, and M. Scheutwinkel. 1987. Screening of the food additive propionic acid for genotoxic properties. Food Chem. Res.25:287–290.
2.
Blommaert, F. A., C. Michael, P. M. A. B. Terheggen, F. M. Muggia, V. Kortes, J. H. Schornagel, A. A. M. Hart, and L. den Engelse. 1993. Drug-induced DNA modification in buccal cells of cancer patients receiving carbo-platin and cisplatin combination chemotherapy, as determined by an immuno-cytochemical method: interindividual variation and correlation with disease response. Cancer Res.53:5669–5675.
3.
Hamilton, T. C., M. A. Winker, K. G. Louie, G. Batist, B. C. Behrens, T. Tsuruo, K. R. Grotzinger, W. M. McKoy, R. C. Young, and R. F. Ozols.1985. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and-sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol.34:2583–2589.
4.
Hengstler, J.G., J. Fuchs, and F. Oesch. 1992. DNA strand breaks and DNA crosslinks in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res.52:5622–5626.
5.
Kelly, S. L., A. Basu, B. A. Teicher, M. P. Hacker, D. H. Hamer, and J. S. Lazo. 1988. Overexpression of metallothionein confers resistance to anti-cancer drugs. Science241:1813–1815.
6.
Kohn, A., M. Donchin, J. Y. Jacobs, Y. Horn, Y. Gibor, F. Fish, G. Riesenfeld, F. Kirenberg, I. Lampert, A. Halachim, and M. Herzberg.1988. Detection of genotoxic substances in cancer patients receiving antineoplastic drugs. Ann N.Y. Acad. Sci.534:776–791.
7.
Lippard, S. J.1982. New chemistry of an old molecule: cis-(Pt(NH3)2Cl2). Science218:1075–1082.
8.
Masuda, H., T. Tanaka, H. Matsuda, and I. Kusaba. 1990. Increased removal of DNA bound platinum in an human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res.50:1863–1866.
9.
Nagai, N., K. Hotta, H. Yamamura, and H. Ogata. 1995. Effects of sodium thio-sulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother. Pharmacol.36:404–410.
10.
Nagai, N., M. Kinoshita, H. Ogata, D. Tsujino, Y. Wada, K. Someya, T. Ohno, K. Masuhara, Y. Tanaka, K. Kato, H. Nagai, A. Yokoyama, and Y. Kurita. 1996. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother. Pharmacol.39:131–137.
11.
Oesch, F., J. G. Hengstler, M. Arand, and J. Fuchs.1995. Detection of primary DNA damage: applicability to biomonitoring of genotoxic occupational exposure and in clinical therapy. Pharmacogenetics5:S118–S122.
12.
Oshita, F., N. Yamamoto, M. Fukuda, Y. Ohe, T. Tamura, K. Eguchi, T. Shinkai, and N. Saijo. 1995. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Cancer Res.55:2334–2337.
13.
Quillardet, P., and M. Hofnung. 1985. The SOS chromotest, a colorimetric bacterial assay for genotoxins: procedures. Mutat. Res.147:65–78.
14.
Reed, E., and K. W. Kohn. 1982. Platinum analogues. In Cancer chemotherapy: Principle and practice, ed. B. A. Chabner and J. M. Collins, 465–490. Philadelphia: J. B. Lippincott.
15.
Reed, E., R. F. Ozols, R. Tarone, S. H. Yuspa, and M. C. Poirier.1987. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc. Natl. Acad. Sci. U.S.A.84:5024–5028.
16.
Scanlon, K. J., and M. Kashani-Sabet. 1988. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc. Natl. Acad. Sci. U.S.A.85:650–653.
17.
Teicher, B. A., S. A. Holden, M. J. Kelley, J. C. Shea, C. A. Cucchi, A. Rosowsky, W. D. Henner, and E. I. Frei.1987. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res.47:388–393.
18.
Vancurova, M., J. Prochazkova, and V. Srb. 1985. Monitoring of effects of cis-diamminedichloroplatinum II (Platidiam). Part II. Tests for mutagenic activity in the indicator system of Salmonella typhimurium his–strains (Ames test). Neoplasma32:307–312.
19.
Vermorken, J. B., W. J. van der Vijgh, I. Klein, H. E. Gall, C. J. van Groeningen, G. A. Hart, and H. M. Pinedo. 1986. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin. Pharmacol. Ther.39:136–144.
20.
Vojtekova, H., J. Svorc, and S. Miertus. 1990. The SOS chromotest study on cisplatin: The genotoxicity evaluation and analytical determination in human urine. Neoplasma37:667–674.
21.
von der Hude, W., C. Behm, R. Guertler, and A. Basler. 1988. Evaluation of the SOS chromotest. Mutat. Res.203:81–94.
22.
Zhen, W., C. J. Link, P. O'Connor, E. Reed, R. Parker, S. B. Howell, and V. A. Bohr. 1992. Increased gene-specific repair of cisplatin interstrand crosslinks in cisplatin-resistant human ovarian cancer cell line. Mol. Cell. Biol.12:3689–3698.
23.
Zwelling, L. A., T. Anderson, and K. W. Kohn. 1979. DNA-protein and DNA interstrand crosslinking by cis-and trans-platinum(II)diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res.39:365–369.
24.
Zwelling, L. A., S. Michaels, S. Schwartz, P. Dobson, and K. W. Kohn. 1981. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res.41:640–649.
